1 result(s) search for keyword(s) 'Neoplasm Staging'    

Three weekly irinotecan and bolus 5-fluorouracil combination in the first line treatment of advanced gastric cancer - a single institution experience / Mohamed Mesmoudi 

Public ISBD Title : Three weekly irinotecan and bolus 5-fluorouracil combination in the first line treatment of advanced gastric cancer - a single institution experience Authors: Mohamed Mesmoudi, Author ; Tarik Mahfoud, Author ; Samir Ahid, Author ; Nabil Ismaili, Author ; Saber Boutayeb, Author ; Hassan Errihani, Author Publisher: Casablanca [Morroco] : Université Mohammed VI des Sciences de la santé Publication Date: 2016 Series: International Journal of Medicine and Surgery, ISSN 2336-0313 No. 3(1) Pagination: p.18-21, fig., tab. Layout: Journal Article ISSN (or other code): 2336-0313 Languages : English Keywords: Stomach Neoplasms  Neoplasm Staging  irinotecan [Supplementary Concept]  Morocco Abstract: Background: The goal of this study is to determine the efficacy and toxicity of a non-platinum based chemotherapy combination using irinotecan associated to bolus 5-FU as first line treatment in advanced gastric cancer. Materiel and methods: Retrospective analysis of a population of patients treated for metastatic and locally advanced gastric cancer with irinotecan and 5-FU as upfront chemotherapy. Results: Thirteen patients were enrolled. The median age was 56 years. Seven patients were males and six were of females. Ten patients had a metastatic disease and three patients had a locally advanced disease. Patients received a total number of 43 cycles of chemotherapy. Overall response rate was 38,4%, median time to progression (TTP) was 3 months, and median overall survival was 4 months. Three patients (23,1%) presented grade 3 /4 neutropenia complicated with an infectious episode with fever in two cases, three patients (23,1%) required blood transfusion for a grade 4 anemia, and one patient (7,6%) was hospitalized for a severe episode of diarrhea. Conclusion: Three weekly irinotecan and bolus 5-FU is an interesting combination as first line treatment of advanced gastric cancer; designed clinical trials are needed to confirm the activity of this combination Link for e-copy: http://www.mbmj.org/index.php/ijms/article/view/95/111 Three weekly irinotecan and bolus 5-fluorouracil combination in the first line treatment of advanced gastric cancer - a single institution experience [] / Mohamed Mesmoudi, Author ; Tarik Mahfoud, Author ; Samir Ahid, Author ; Nabil Ismaili, Author ; Saber Boutayeb, Author ; Hassan Errihani, Author . - Casablanca (Morroco) : Université Mohammed VI des Sciences de la santé, 2016 . - p.18-21, fig., tab. : Journal Article. - (International Journal of Medicine and Surgery, ISSN 2336-0313; 3(1)) . ISSN : 2336-0313 Languages : English Keywords: Stomach Neoplasms  Neoplasm Staging  irinotecan [Supplementary Concept]  Morocco Abstract: Background: The goal of this study is to determine the efficacy and toxicity of a non-platinum based chemotherapy combination using irinotecan associated to bolus 5-FU as first line treatment in advanced gastric cancer. Materiel and methods: Retrospective analysis of a population of patients treated for metastatic and locally advanced gastric cancer with irinotecan and 5-FU as upfront chemotherapy. Results: Thirteen patients were enrolled. The median age was 56 years. Seven patients were males and six were of females. Ten patients had a metastatic disease and three patients had a locally advanced disease. Patients received a total number of 43 cycles of chemotherapy. Overall response rate was 38,4%, median time to progression (TTP) was 3 months, and median overall survival was 4 months. Three patients (23,1%) presented grade 3 /4 neutropenia complicated with an infectious episode with fever in two cases, three patients (23,1%) required blood transfusion for a grade 4 anemia, and one patient (7,6%) was hospitalized for a severe episode of diarrhea. Conclusion: Three weekly irinotecan and bolus 5-FU is an interesting combination as first line treatment of advanced gastric cancer; designed clinical trials are needed to confirm the activity of this combination Link for e-copy: http://www.mbmj.org/index.php/ijms/article/view/95/111

Copies

Barcode	Call number	Media type	Location	Section	Status
No copy